Pfizer Inc. (NYSE:PFE) Receives Average Recommendation of “Hold” from Brokerages

Pfizer Inc. (NYSE:PFE) has been assigned an average recommendation of “Hold” from the nineteen research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $28.0588.

Several equities analysts recently issued reports on the company. Morgan Stanley dropped their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. HSBC restated a “buy” rating and set a $29.00 price target on shares of Pfizer in a report on Wednesday, December 10th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Wednesday. Bank of America decreased their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Finally, Scotiabank assumed coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target on the stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PFE. Fiduciary Alliance LLC boosted its stake in shares of Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after purchasing an additional 46,043 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Pfizer during the 3rd quarter valued at $3,019,000. Vista Investment Partners LLC increased its holdings in shares of Pfizer by 236.1% in the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after acquiring an additional 48,900 shares during the period. Money Concepts Capital Corp raised its position in shares of Pfizer by 29.9% in the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after acquiring an additional 57,188 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. lifted its stake in shares of Pfizer by 76.4% during the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock worth $2,784,000 after purchasing an additional 47,319 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $27.24 on Friday. Pfizer has a 12 month low of $20.92 and a 12 month high of $27.69. The stock has a market capitalization of $154.88 billion, a P/E ratio of 20.03 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm’s 50 day moving average is $25.61 and its 200 day moving average is $25.10.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the prior year, the company posted $0.63 EPS. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat and GLP‑1 topline: Pfizer reported upside on revenue and EPS and released positive Phase 2b results for its lead GLP‑1 candidate (strong placebo‑adjusted weight loss), which helped lift sentiment around a new growth leg. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: Management outlines obesity strategy: Pfizer execs signaled the company is “back in the obesity race,” emphasizing development plans and commercialization intent after the encouraging GLP‑1 data. Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
• Positive Sentiment: FDA grants Priority Review for HYMPAVZI sBLA: The agency accepted a supplemental biologics license application to expand HYMPAVZI’s indication to pediatric and inhibitor populations in hemophilia, which could broaden revenue opportunity if approved. FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Mid‑stage obesity candidate complete: Pfizer announced completion of a mid‑stage trial for PF‑07976016, adding to its GLP‑1/obesity development cadence and potential registration pathway. Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016
• Positive Sentiment: Pipeline & M&A push into oncology and obesity: Analysts and coverage note Pfizer is lining up ~20 pivotal studies after ~ $9B of 2025 M&A, leaning on Seagen assets and AI tools to accelerate R&D — a multi‑year growth story. Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
• Positive Sentiment: Income investor attention: Pfizer appears on recent high‑yield dividend stock lists, which can support demand from yield‑focused investors. 3 High-Yield Dividend Stocks Perfect For Retirees
• Neutral Sentiment: Cost‑savings / affordability program: Pfizer launched a TrumpRx program offering discounts on ~30 medicines — positive for patient access and PR, but the near‑term financial impact is unclear. Pfizer Launches Cost-Savings Program on TrumpRx
• Neutral Sentiment: Analyst views mixed: Coverage notes cautious upside — bullish pipeline/AI drivers balanced by execution risk, time to commercialization, and competitive pressure in GLP‑1s. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
• Negative Sentiment: Early‑stage trial halted: Pfizer paused an early‑stage study for PF‑07258669 in older adults, introducing a specific clinical risk that could require program adjustments. Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.